Vyome Holdings Inc., a clinical-stage company focused on immuno-inflammatory conditions, announced promising interim results from a Phase 2 clinical study of its lead program, VT-1953. VT-1953 is a topical agent designed to address symptoms such as putrid smell and pain in patients with malignant fungating wounds (MFW), an inflammatory condition affecting an estimated one million cancer patients. The interim results were presented as part of the company's first quarter report following its Nasdaq listing. Further milestones and updates related to the program are anticipated as development progresses.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vyome Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251118862654) on November 18, 2025, and is solely responsible for the information contained therein.